However, while YM155 is recognized as a highly potent inhibitor of survivin expression in vitro, it exhibited very limited anti-tumor efficacy when used alone or in combination with chemotherapeutic agents in multiple phase 1 and phase 2 clinical trials, which can most likely be ascribed to the chemical instability of YM155 [35]. The gene discussed is BIRC5; the disease is neoplasm.